Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2024-04-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天健会计师事务所对天士力非经营性资金占用及其他关联资金往来情况的专项审计说明
Regulatory Filings
2024-04-15 Chinese
天士力2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the 2023 annual report summary of TianShiLi Pharmaceutical Group Co., Ltd. It contains detailed financial performance data, operational highlights, R&D pipeline updates, marketing strategies, and future plans for the company. The text includes audited financial figures, profit distribution proposals, and comprehensive management discussion and analysis of the company's yearly activities. The length is substantial (15,000 characters), and the content is consistent with a full annual report rather than a brief announcement or a presentation. There is no indication that this is merely an announcement of a report or a certification document. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-15 Chinese
天士力关于2024年度为子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the provision of guarantees by the parent company to its subsidiaries for the year 2024. It details the guarantee amounts, the companies involved, the financial status of the subsidiaries, and the board's approval of the guarantee plan. There is no indication that this is a full financial report, audit report, or earnings release. Instead, it is a regulatory announcement about financing-related guarantees and risk disclosures. The document is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company to subsidiaries.
2024-04-15 Chinese
天士力2023年度利润分配预案
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan (dividend announcement) for the fiscal year 2023 by TianShiLi Pharmaceutical Group Co., Ltd. It details the dividend per share, total dividend amount, and the decision-making process including board and supervisory opinions. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend amount and related shareholder information. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2024-04-15 Chinese
天士力2023年度审计报告
Regulatory Filings
2024-04-15 Chinese
天士力关于续聘2024年度会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (auditor) for the fiscal year 2024. It details the auditor's qualifications, independence, audit fees, and the approval process by the board and audit committee. It does not contain any financial statements or audit reports themselves, but rather is a formal notice about the auditor appointment. The document length is 2965 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement about auditor appointment, not the audit report or annual report itself.
2024-04-15 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.